Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any gender
• People with a good general health and activity level (rated 0 or 1 on a standard performance scale used by doctors)
• People who have been newly diagnosed with non-small cell lung cancer (NSCLC) that has been confirmed by a tissue biopsy, is considered surgically removable, and is classified as Stage II, IIIA, or IIIB (with a specific lymph node involvement called N2), and who have not yet received any treatment for it
• People whose cancer can be measured on scans using standard medical criteria
• People who can provide a tumour tissue sample before the trial begins, for testing including protein and gene marker analysis
• People whose lung function is judged by their doctor to be adequate to withstand lung surgery
• People whose tumour tissue testing has confirmed the absence of certain specific gene changes (EGFR and ALK sensitive mutations)
• People with healthy enough bone marrow, liver, and kidney function, as confirmed by blood tests meeting specific minimum levels set by the trial
• People who understand the study and are willing to sign a consent form
• Women of childbearing age who have a negative pregnancy blood test within 3 days before the first dose

Who may not be able to join:

• People whose cancer cannot be surgically removed, or has spread to other parts of the body, including those with certain advanced-stage disease features as defined by specific medical guidelines
• People whose NSCLC is located in a specific area at the top of the lung (superior sulcus), or who have a large cell neuroendocrine cancer or sarcomatoid tumour type
• People whose tumour testing shows certain specific gene changes (EGFR sensitive mutations or ALK translocation) — testing for these is required for people with non-squamous cell cancer types
• People who have previously received any systemic cancer treatment for early-stage NSCLC, including experimental treatments
• People who have a history of, or currently have, lung inflammation or scarring (pneumonitis or interstitial lung disease) that has required steroid medication
• People with active tuberculosis
• People with an active infection that requires treatment through the whole body (systemic treatment)
• People with a known or suspected condition where the immune system attacks the body (autoimmune disorder) or a weakened immune system — with exceptions for well-controlled underactive thyroid or well-controlled Type 1 diabetes
• People with uncontrolled active hepatitis B or active hepatitis C, based on specific blood test results (people with low hepatitis B levels who have been on antiviral treatment for at least 14 days and agree to continue may still be considered — confirm with trial site)
• People known to have HIV infection
• People who have received a live vaccine within 30 days before the first dose (examples include vaccines for mumps, rubella, measles, chickenpox, yellow fever, rabies, BCG, and live typhoid — inactivated vaccines are allowed)
• People with moderate to severe nerve damage in the hands or feet (grade 2 or higher peripheral neuropathy)
• People who have previously been treated with certain immune checkpoint drugs (PD-1/PD-L1 agents or similar drugs targeting T cell receptors such as CTLA-4 or OX-40)
• People who have had a serious allergic reaction to other monoclonal antibody medications
• People with a known serious allergy to any of the chemotherapy drugs used in this trial (pemetrexed, paclitaxel, docetaxel, cisplatin, or carboplatin) or their associated preventive medications
• People with serious or uncontrolled existing health conditions, including certain heart or blood flow problems, recent stroke or other brain blood vessel events, or significant liver cirrhosis within the past 6 months
• People whose health history, current conditions, or test results may interfere with the trial or would not be in their best interest, as assessed by the investigating doctors
• People who have had another cancer within the past 5 years — with possible exceptions for certain low-risk cancers that have been fully treated (such as early-stage cervical, skin, or breast duct cancers), confirm with trial site

Important: Always verify eligibility with the trial site directly before applying.